



Ferring Pharmaceuticals Methodological note for HCP/ORDM/HCO disclosure 2025

Data year: [2025]

Year of publication: [2026]

Contents

1	Definitions	2
1.1	Recipients.....	2
1.2	Kind of ToVs	3
2	Disclosure's Scope.....	3
2.1	Products concerned.....	3
2.2	Company concerned.....	3
2.3	Excluded ToVs.....	3
2.4	ToVs date	4
2.5	Direct ToVs	4
2.6	Indirect ToVs.....	4
2.7	Non-monetary ToVs.....	4
2.8	ToVs in case of partial attendances or cancellation and refund.....	4
2.9	Cross-border activities	4
2.10	R&D.....	4
2.11	Voluntary disclosure.....	4
3	Specific considerations.....	4
3.1	Country unique identifier	4
3.2	Self-incorporated HCP	5
3.3	Multi-year agreements	5
3.4	Country specificities.....	5
3.5	Quality Checks	5

4	Data protection legal basis	5
4.1	Consent collection	5
4.2	Legitimate interests	5
5	Form of disclosure.....	5
5.1	Date of publication.....	5
5.2	Disclosure platform.....	6
5.3	Disclosure language	6
6	Disclosure financial data.....	6
6.1	Currency.....	6
6.2	VAT included or excluded	6
6.3	Calculation rules.....	6
7	Additional Information.....	6

1 Definitions

1.1 Recipients

Ferring regularly works with HCP/HCOs. This Methodological note provides a summary of the methodologies used by Ferring Pharmaceuticals Limited in line with the ABPI Code of Practice 2024 to identify and report on Transfers of Value made directly or indirectly by Ferring, to or for the benefit of HCP/HCOs.

- HCP: An individual who is qualified to prescribe, administer, purchase, supply or recommend a Medicinal Product whose primary practice, principal professional address or place of incorporation is in UK
- HCO: Any legal entity (i) that is a healthcare, medical or scientific association or organization (irrespective of the legal or organizational form) such as a hospital, clinic, foundation, university or other teaching institution or learned society, whose business address, place of incorporation or primary place of operation is in UK or (ii) through which one or more HCPs provide services.
- ORDM: Particularly includes someone with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who is not a health professional.

If the ToV is made to a retired health professionals or other relevant decision maker, how is data relating to deceased health professionals or other relevant decision makers managed?

Not applicable

How is data relating to deceased health professionals or other relevant decision makers managed?

Not applicable

1.2 Kind of ToVs

Donations, Grants: Providing funds, benefits in-kind, or services freely given for the purpose of supporting healthcare, scientific research or education, with no consequent obligation on the recipient organisation, institution and the like to provide goods or services to Ferring to the benefit of Ferring in return. Donations and grants to individuals are prohibited.

Sponsorship: a contribution, financial or otherwise, in whole or in part provided by or on behalf of Ferring, towards an activity (including an event/meeting or material) performed, organised, created by a healthcare organisation, patient organisation or other independent organisation.

Support: the provision of a financial contribution, in whole or in part, whether paid directly or indirectly to individual health professionals or other relevant decision makers to attend events/meetings, and includes payment for registration fees, travel and accommodation.

Contracted services as consultants and advisors are made with health professionals, other relevant decision makers or their employers on their behalf, healthcare organisations, patient organisations, individuals representing patient organisations, and members of the public, including patients and journalists, for services such as speaking at and chairing meetings, involvement in medical/scientific studies, clinical trials or training services, writing articles and/or publications, participation at advisory board meetings, and are disclosed as ToV. The remuneration for the services reflects the fair market value of the services provided, and includes payment for registration fees, travel and accommodation.

ToV payments in relation to research and development work, include payment for services for the conduct of clinical trials and real world evidence generation.

Cross border ToV from Ferring affiliates to UK HCPs and HCOs for contracted services provided are disclosed as ToV. The remuneration for the services reflects the fair market value of the services provided and includes payment for registration fees, travel and accommodation. If one HCP/HCO has several countries of practices / registration, all the countries in which the HCP practices disclose the ToV; for an HCO the country where the HCO is legally based discloses the ToV (business address, place of incorporation, or primary place of operation).

No collaborative working projects were conducted in 2025.

2 Disclosure's Scope

2.1 Products concerned

The disclosure includes ToV made in connection with the development or sale of prescription only medicines.

Ferring did not have any over-the-counter (OTC) medicine transfers of value for 2025.

No transfer of value was made for medical devices in 2025.

2.2 Company concerned

TOVs disclosed are those made to UK HCPs, ORDMs or HCOs on behalf of Ferring Pharmaceuticals Ltd, UK and made by overseas affiliates or head offices of Ferring Pharmaceuticals Ltd.

2.3 Excluded ToVs

The following are not ToV for the purposes of this disclosure:

- ordinary course purchases and sales of medicines by and between Ferring and a health professional or a healthcare organisation
- samples of medicines provided in accordance with Clause 21
- ToV provided in accordance with Clauses 10.5, 10.6
- subsistence provided to health professionals and other relevant decision makers in accordance with Clause 10.1.

2.4 ToVs date

Date of TOV is the date of the effective payment to the recipient in calendar year 2025.

2.5 Direct ToVs

Direct TOVs are those made directly by Ferring for the benefit of a Recipient.

2.6 Indirect ToVs

Indirect TOVs are those made on behalf of Ferring for the benefit of a Recipient, or those made through a Third Party and where Ferring knows or can identify the Recipient that will benefit from the Transfer of Value.

2.7 Non-monetary ToVs

No non-monetary transfers of value applicable.

2.8 ToVs in case of partial attendances or cancellation and refund

In case of partial attendance or cancellation, or services not delivered, but value was transferred anyway e.g. according to contract clause, the transferred value is disclosed. If no value was transferred, the information on the TOV is not part of disclosure.

2.9 Cross-border activities

Cross border transfer of values from Ferring affiliates towards UK HCPs and HCOs are included in the disclosure submission, and are approved on a Global Ferring platform by a UKIE signatory, as well as the signatory from the affiliate country where the activity took place. If one HCP/HCO has several countries of practices / registration, all the countries in which the HCP practices will disclose the transfer of value / for an HCO the country where the HCO is legally based discloses the ToV (business address, place of incorporation, or primary place of operation).

2.10 R&D

All payments to HCPs and HCOs related to research and development are disclosed as one aggregate figure under R&D Transfer of Value. This includes Investigator Initiated Studies. Costs that are subsidiary to these R&D activities are also included in the aggregate amount.

ToVs related to medical writing and editorial support, such as for case studies, congress write ups, article and abstracts, manuscripts, poster, clinical management guidelines and supplements, made directly or indirectly to an HCO/HCP, are disclosed under the "Fees for Service and Consultancy" in the name of the benefitting HCP/HCO.

2.11 Voluntary disclosure

Not applicable

3 Specific considerations

3.1 Country unique identifier

Not applicable

3.2 Self-incorporated HCP

In the event of a HCP running a private company or partnership or charity for the purpose of their private income, any ToV made to that organisation will be regarded for disclosure purposes as a payment to the HCP directly.

3.3 Multi-year agreements

ToV is disclosed in the year the activity was conducted (eg. fee for service) or donations/grants/sponsorship was received by the HCP/HCO for multi-year agreements.

3.4 Country specificities

Ferring UKIE has not worked with any other pharmaceutical company in 2025.

3.5 Quality Checks

All interactions with HCPs/HCOs/ORDMs are documented on the Financial Agreement or Meetings Acceptance form; this data is input to the disclosure template and then cross-checked against the said agreements.

4 Data protection legal basis

4.1 Consent collection

- Consent to disclose ToV is collected through Financial Agreements, meeting acceptance forms or Service Agreements made with HCPs and HCOs
- Agreements to disclose are written into all our agreements with HCPs and HCOs. They are also given the opportunity to not consent to disclose ToV within the agreements, and if they do their data is aggregated within our submission
- In 2025 we had no parties who partially agreed to disclose.
- If any party decides to withdraw consent at the point of signing an agreement their data is automatically aggregated within our disclosure.
- If consent is withdrawn once the submission is made, the submission is amended to aggregate their data and resubmitted in the disclosure portal.

4.2 Legitimate interests

The majority of ToV disclosures are based on 'Consent' to publish a HCP/ORDM name and practice address against the value they received on Disclosure UK. The terms of processing data under Clear and explicit agreement from each individual is documented with signatures on the Financial Agreement, meeting acceptance form or Service Agreement.

Ferring also relies on legitimate interests as its lawful basis for publicly disclosing ToVs to HCP/ORDM where consent is not documented, unless an HCP/ORDM exercises their right to object to disclosure, and where such objection overrides Ferring's legitimate interests in disclosure. In such cases where HCP/HCO/ORDM object to disclosure, the ToV is disclosed as an aggregate amount.

The Financial agreement to document provision of funding has a Tick box that states – "By ticking this box, the Recipient has specified that it wishes to opt out of individual disclosure of its TOV and agrees that, to the extent permitted by the Codes, Ferring will disclose its TOV in its aggregate amount."

Information about HCOs is not considered personal data therefore a lawful basis is not required to publish organisation names and addresses on Disclosure UK.

5 Form of disclosure

5.1 Date of publication

30/06/26

5.2 Disclosure platform

Disclosure UK – www.disclosureuk.org.uk

5.3 Disclosure language

English

6 Disclosure financial data

6.1 Currency

Our 2025 disclosures are submitted in GBP inline with the Code.

Any payments made in foreign currencies such as Euro's have been converted using the exchange rates listed on The Bank of England on the 16th March 2026 [GBP exchange rates | Bank of England | Database](#)

6.2 VAT included or excluded

VAT is not included in the payments

6.3 Calculation rules

In 2025 we had no non-monetary value payments.

7 Additional Information

Not applicable.